Phaseline

Companies › Traws Pharma

Traws Pharma: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRX-100
CEN inhibitor
–Phase 2Influenza; Healthy VolunteerDec 2026
Ratutrelvir (83-0060)
Covalent inhibitor of SARS-CoV-2 main protease (Mpro; 3CL)
–Phase 2COVID - 19–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07157007Ratutrelvir (83-0060)Phase 2COVID - 19Infectious diseaseFeb 2026
NCT07371650TRX-100Phase 2InfluenzaInfectious diseaseDec 2026
NCT07526506TRX-100Phase 1Healthy VolunteerInfectious diseaseFeb 2027

From the company's SEC filings

Cash of $5m on 2026-06-30; operating cash outflow about $20m a year; runway about 3 months at that burn, to Sep 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

60 Degrees Pharmaceuticals Lakewood-Amedex Acurx Pharmaceuticals Amplexd Therapeutics Sano Chemicals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.